Shares of Outlook Therapeutics OTLK moved higher by 2.8% in pre-market trading after the company reported Q3 results.
Earnings per share were down 133.33% year over year to ($0.07), which were in line with the estimate of ($0.07).
Revenue of $0 unchanged by 0.00% year over year, which missed the estimate of $320,000.
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Recent Stock Performance
52-week high: $4.26
Company's 52-week low was at $0.58
Price action over last quarter: Up 15.56%
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.